Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Nature Medicine

• Publication date

  2021-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41591-020-01188-3PMID 33558722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeted Therapy and Immunotherapy in Melanoma.

  2022cited by this paper
• A phase II study to evaluate the need for > two doses of nivolumab + ipilimumab combination (combo) immunotherapy.

  2020cited by this paper
• A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma

  2019cited by this paper
• Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy

  2019cited by this paper
• Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

  2019cited by this paper
• Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

  2019cited by this paper
• Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.

  2019cited by this paper
• Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.

  2019cited by this paper
• Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

  2019cited by this paper
• Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

  2019cited by this paper
• Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

  2019cited by this paper
• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

  2019cited by this paper
• Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

  2018cited by this paper
• Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

  2018cited by this paper
• Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

  2018cited by this paper
• Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

  2018cited by this paper
• Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

  2018cited by this paper
• Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma

  2018cited by this paper
• Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

  2017cited by this paper
• Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

  2017cited by this paper
• Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma

  2017cited by this paper
• Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

  2017cited by this paper
• Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma

  2017cited by this paper
• Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease

  2016cited by this paper
• Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

  2014cited by this paper
• Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

  2014cited by this paper
• First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer

  2014cited by this paper
• Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.

  2012cited by this paper
• Final version of 2009 AJCC melanoma staging and classification.

  2009cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.

  2006cited by this paper
• Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival.

  2005cited by this paper

• Treatment effect of neoadjuvant immunotherapy in melanoma correlates with tumor burden: meta-analysis of reported clinical trials.

  2026cites this paper
• The capability of deep-radiomics to predict pathological response to neoadjuvant immunochemotherapy in non–small cell lung cancer: a retrospective multicenter study

  2026cites this paper
• Perioperative immunotherapy for advanced resectable melanoma: a cost-effectiveness analysis.

  2026cites this paper
• Neoadjuvant therapy in skin cancer: current evidence and future perspectives.

  2026cites this paper
• Expert consensus on neoadjuvant immunochemotherapy for resectable locally advanced oral squamous cell carcinoma

  2026cites this paper
• From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma

  2026cites this paper
• Surgical Management of Stage IV Melanoma: Clinical, Molecular, and Therapeutic Considerations

  2026cites this paper
• Sequential ROS-Responsive Micelles in Combination with a Multifunctional Hydrogel for Neoadjuvant Chemo-Photothermal Therapy Against Melanoma Recurrence.

  2026cites this paper
• Newly Identified Transcriptomic Biomarkers and Gene Signature of Pathological Complete Response to Induction Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

  2026cites this paper
• Priorities for local immunotherapy research and drug development

  2026cites this paper
• Evolution of the sentinel lymph node procedure following the approval of adjuvant anti-PD-1 therapy for stage IIB and IIC melanoma: A multicenter study from RICMEL database.

  2026cites this paper
• Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

  2026cites this paper
• Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms.

  2026cites this paper
• Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant trials (PATHdata): Results of a Society for Immunotherapy of Cancer multi-institutional reproducibility study.

  2026cites this paper
• Biomarker analysis of circulating tumor DNA in clinical stage III melanoma patients treated with neoadjuvant immunotherapy combined with targeted therapy

  2026cites this paper
• Biomarkers of Immunotherapy Response in Surgical Oncology

  2026cites this paper
• Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial

  2026cites this paper
• Pancreatic volume and immune biomarkers predict checkpoint inhibitor–associated autoimmune diabetes in humans

  2025cites this paper
• Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448

  2025cites this paper
• Response-Based Immunotherapy in Melanoma

  2025cites this paper
• Neoadjuvant treatment in advanced resectable melanoma and the need for a predictive biomarker - is pathologic complete response (pCR) the answer?

  2025cites this paper
• Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study

  2025cites this paper
• Buoyant mass reveals distinct T cell states predictive of checkpoint response

  2025cites this paper
• Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade.

  2025cites this paper
• Special Issue on Skin Cancers of the Head and Neck

  2025cites this paper
• Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)

  2025cites this paper
• TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study

  2025cites this paper
• Clinical Approaches for the Management of Skin Cancer: A Review of Current Progress in Diagnosis, Treatment, and Prognosis for Patients with Melanoma

  2025cites this paper
• Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

  2025cites this paper
• Melanoma neoadjuvant treatment: review and update of recent trials

  2025cites this paper
• Current and emerging opportunities for deintensification of systemic therapies in melanoma: A scoping review.

  2025cites this paper
• Effect of neoadjuvant therapy on survival outcomes in patients with melanoma: a systematic review and meta-analysis

  2025cites this paper
• Histopathological Response After Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcomas

  2025cites this paper
• Pathologic Response and Survival After Neoadjuvant Immunotherapy for Resectable Mucosal HNSCC: A Systematic Review and Meta-Analysis.

  2025cites this paper
• Melanoma Skin Cancer: A Comprehensive Review of Current Knowledge

  2025cites this paper
• Rare primary anorectal malignant melanoma presenting with painless hematochezia: a case report

  2025cites this paper
• Cross-sectional study of long-term Health-Related Quality of Life in stage III melanoma patients receiving neo-adjuvant versus adjuvant immune checkpoint inhibitors.

  2025cites this paper
• Pathologic Complete Response and Survival in Rectal Cancer

  2025cites this paper
• A comprehensive review and case series of adjuvant and neoadjuvant therapies in acral melanoma with emerging insights from CT DNA testing

  2025cites this paper
• Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma

  2025cites this paper
• Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma

  2025cites this paper
• How to treat BRAF mutant metastatic melanoma?

  2025cites this paper
• The Role of Neoadjuvant Immunotherapy in the Management of High-Risk Stage III Resectable Melanoma: A Literature Review

  2025cites this paper
• Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).

  2025cites this paper
• Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial

  2025cites this paper
• Facts & Hopes: towards the next quantum leap in melanoma.

  2025cites this paper
• Tumor-draining lymph nodes - friend or foe during immune checkpoint therapy?

  2025cites this paper
• Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025

  2025cites this paper
• Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial

  2025cites this paper
• FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma

  2025cites this paper
• Toward Functional Biomarkers of Response to Neoadjuvant Oncolytic Virus in Stage II Melanoma: Immune-Förster Resonance Energy Transfer and the Dynamic Tumor Immune Microenvironment

  2025cites this paper
• The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy and Radiomics Based Technologies for Immuno-Oncology Biomarker Discovery and Application.

  2025cites this paper
• Evidence for a reduction in number of cycles of immune checkpoint inhibitors.

  2025cites this paper
• Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial

  2025cites this paper
• Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?

  2025influential citation
• Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma

  2025cites this paper
• Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges

  2025cites this paper
• Neoadjuvant Immunotherapy in Cutaneous Squamous Cell Carcinoma: Systematic Literature Review and State of the Art

  2025cites this paper
• Predictive Biomarkers for Immune Checkpoint Inhibitor Therapy in Advanced Melanomas.

  2025cites this paper
• Systemic Therapy for Melanoma: What Surgeons Need to Know.

  2025cites this paper
• Emerging clinical applications of single-cell RNA sequencing in oncology

  2025cites this paper
• [Adjuvant and neoadjuvant treatments of melanoma].

  2025cites this paper
• Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade

  2025cites this paper
• An evaluation of nivolumab and ipilimumab for the treatment of resectable stage III melanoma

  2025cites this paper
• Translational selenium nanomedicine synergizes with nab-paclitaxel to enhance antitumor effects in esophageal squamous cell cancer via selenoprotein N-mediated ER stress

  2025cites this paper
• Longitudinal analysis reveals dynamic changes in histopathologic features in responders to neoadjuvant treatment in a stage III BRAF-mutant melanoma cohort.

  2025cites this paper
• Adjuvante und neoadjuvante Therapie des Melanoms

  2025cites this paper
• Clinical Applications of the Molecular Landscape of Melanoma: Integration of Research into Diagnostic and Therapeutic Strategies

  2025cites this paper
• Neoadjuvante Therapie mit Immuncheckpoint‐Inhibitoren bei Melanompatienten: eine retrospektive Real‐Life‐Studie

  2025cites this paper
• Neoadjuvante Therapie des Melanoms

  2025cites this paper
• A Review of Neoadjuvant PD-1 Inhibitors in the Setting of Cutaneous Malignancies.

  2025cites this paper
• The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types

  2025cites this paper
• Advancing equitable access to innovation in breast cancer

  2025cites this paper
• NAVIGATING THE CHALLENGES OF IMMUNOTHERAPY AS A NEOADJUVANT TREATMENT FOR LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: A REVIEW OF THE EVIDENCE FROM THE LITERATURE.

  2025cites this paper
• Dabrafenib and trametinib vs anti-PD(L)1 for the adjuvant treatment of locally advanced BRAF-mutant melanoma: a systematic review and meta-analysis

  2025cites this paper
• The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma.

  2025cites this paper
• Accuracy of PET–CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment

  2025cites this paper
• Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland

  2025cites this paper
• Pathological responses to neoadjuvant immunochemotherapy: implications for survival and recurrence in patients with locally advanced esophageal squamous cell carcinoma

  2025cites this paper
• Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers

  2025cites this paper
• Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma.

  2025cites this paper
• Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort.

  2025cites this paper
• A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease.

  2024cites this paper
• What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?

  2024cites this paper
• Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.

  2024cites this paper
• Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer

  2024cites this paper
• Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.

  2024cites this paper
• Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study.

  2024cites this paper
• Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

  2024cites this paper
• Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

  2024cites this paper
• A Review of Contemporary Guidelines and Evidence for Wide Local Excision in Primary Cutaneous Melanoma Management

  2024cites this paper
• Neoadjuvant therapy for resectable melanoma

  2024cites this paper
• Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.

  2024cites this paper
• Clinical and Histological Response to Talimogene Laherparepvec Therapy in Advanced Melanoma: Impact on Overall Survival.

  2024cites this paper
• Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment.

  2024cites this paper
• Optimal Practices for Suspected Nodal Melanoma-The Role of the General Surgeon.

  2024cites this paper
• Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.

  2024cites this paper
• Easily applicable predictive score for MPR based on parameters before neoadjuvant chemoimmunotherapy in operable NSCLC: a single-center, ambispective, observational study

  2024cites this paper
• Management of acral lentiginous melanoma: current updates and future directions

  2024cites this paper
• Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma

  2024influential citation